OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - MODERNA | Delayed Deutsche Boerse AG 03:51:03 2024-07-16 pm EDT | ||
| 5.49 EUR | -0.72% |
|
| Current month | -2.66% | ||
| 1 month | +0.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 5.49 | -0.72% |
| 24-07-15 | 5.53 | +0.18% |
| 24-07-12 | 5.52 | -0.18% |
| 24-07-11 | 5.53 | -1.07% |
| 24-07-10 | 5.59 | -0.53% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 03:51 pm EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF7QKE |
| ISIN | DE000SF7QKE4 |
| Date issued | 2021-08-10 |
| Strike | 724.2 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.25 € |
|---|---|
| Lowest since issue | 2.03 € |
| Spread | 0.01 € |
| Spread % | 0.18% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
125.1
USD
Average target price
145.9
USD
Spread / Average Target
+16.59%
- Stock Market
- Certificates
- Certificat
